Overcoming Cisplatin Resistance with AMD473
Author Information
Author(s): J Holford, SY Sharp, BA Murrer, M Abrams, LR Kelland
Primary Institution: Institute of Cancer Research
Hypothesis
Can the novel platinum complex AMD473 effectively circumvent cisplatin resistance in ovarian carcinoma cell lines?
Conclusion
AMD473 shows promise in overcoming cisplatin resistance in ovarian cancer cell lines, demonstrating lower resistance factors compared to cisplatin.
Supporting Evidence
- AMD473 showed a lower increase in IC50 value from the most sensitive to the most resistant cell line compared to cisplatin and carboplatin.
- AMD473 demonstrated significantly reduced cross-resistance to cisplatin in resistant cell lines.
- Cellular accumulation of AMD473 was not reduced in cisplatin-resistant cell lines.
Takeaway
Researchers created a new drug called AMD473 that helps fight cancer cells that are resistant to another drug called cisplatin.
Methodology
The study involved testing the growth inhibition of AMD473 in 11 human ovarian carcinoma cell lines and comparing its effectiveness to cisplatin and carboplatin.
Participant Demographics
Human ovarian carcinoma cell lines were used in the study.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website